Surrozen publishes study in ‘Respiratory Research’ on Wnt mimetic tech potential

Surrozen announced publication of data in Respiratory Research highlighting the potential for Surrozen’s Wnt mimetic technologies to treat serious lung diseases like idiopathic pulmonary fibrosis IPF The results observed with systemic administration of Surrozen’s Wnt mimetic antibody in an acute bleomycin model of pulmonary fibrosis demonstrate a Wnt pathway mediated decrease in inflammation and fibrosis and improvement in lung function.”Current treatments for severe lung diseases like IPF aren’t able to regenerate normal, functional tissue,” said Yang Li, Ph.D., Executive Vice President, Research at Surrozen. “This work published in Respiratory Research represents a breakthrough in understanding the role of the Wnt pathway in lung fibrosis and the potential for Wnt mimetics to reduce fibrosis and improve lung function.”